Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspective.

Homeopathy. 2010 Oct;99(4):231-42.Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspective.

Chikramane PS, Suresh AK, Bellare JR, Kane SG. Department of Chemical Engineering, Indian Institute of Technology, Bombay, Adi Shankaracharya Marg, Powai, Mumbai, Maharashtra, India.

Comment in:

Homeopathy. 2010 Oct;99(4):229-30. Abstract Homeopathy is controversial because medicines in high potencies such as 30c and 200c involve huge dilution factors (10⁶⁰ and 10⁴⁰⁰ respectively) which are many orders of magnitude greater than Avogadro's number, so that theoretically there should be no measurable remnants of the starting materials. No hypothesis which predicts the retention of properties of starting materials has been proposed nor has any physical entity been shown to exist in these high potency medicines. Using market samples of metal-derived medicines from reputable manufacturers, we have demonstrated for the first time by Transmission Electron Microscopy (TEM), electron diffraction and chemical analysis by Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES), the presence of physical entities in these extreme dilutions, in the form of nanoparticles of the starting metals and their aggregates.

Copyright © 2010 The Faculty of Homeopathy. Published by Elsevier Ltd. All rights reserved.

Read more: http://www.cbc.ca/consumer/story/2011/01/14/f-homeopathy-naturopathic-marketplace.html#socialcomments#ixzz1B8T9HgtE

Effective Cancer Treatment with Popular Cuban Homeopathic Drug Vidatox

Effective Cancer Treatment with Popular Cuban Homeopathic Drug Vidatox

What is Vidatox?

Vidatox is a drug produced from five protein peptides extracted from the venom of the blue scorpion (Rophalorus junceus), which is endemic to Cuba and which has analgesic, anti-inflammatory and anti-carcinogenic effect in more than 15 different cancer cell lines. The result of 15 years of research, by October 2010 Vidatox had been tested on more than 10,000 cancer patients, some 3,500 of them foreigners, with positive results both in improving quality of life and stopping tumour growth.

Labiofam, a Cuban pharmaceutical laboratory, is set to release a new homeopathic cancer drug to the international market. Marketed as Vidatox, it is the result of work by Cuban biologist, Misael Bordier with the venom of the blue scorpion.

The medication was produced from over 5,000 scorpions of the Rhopalurus junceus variety, native to eastern Cuba. According to the company, it has no contraindications and is compatible with any other oncological treatment.

The company presented the results of its Vidatox research in its first international congress in late September in Havana before some 500 delegates from all parts of the world. Vidatox International Congress: Results of Scientific Research

The Company is all set to register its homeopathic version in coming days and go for its commercial production. The medication, and Labiofam says that its homeopathic version should be registered in the coming days and could be commercially produced immediately. González added that the company would continue research to produce synthetic or biotechnological versions of the compound.

Report on the Current Situation Regarding Vidatox 30 CH (Translated from Spanish)

The use of natural products in traditional and alternative medicine is widely practiced today. In particular, the Poison Scorpion have been little studied and a few years ago began their potential pharmacological evidence.

In Cuba there are 32 species and subspecies of scorpions, including 28 endemic among the most common being the scorpion Rhopalurus junceus the which has been used in traditional medicine to apply under the Cuban stomach in case of urinary retention and improvement of some diseases.

The 30 CH VIDATOX ® is the registered trademark for the drug homeopathic and natural (health record: H-11 – 038 – NO2) obtained from junceus Rhopalurus scorpion venom, endemic to Cuba, indicated as adjunctive therapy in the treatment of symptoms caused by effects of cancer and pain relief. The decision to produce is the result over 15 years of a research project aimed at characterization of the poison, and evaluating their potential as antitumor agent, analgesic, antiinflammatory, and toxicological safety.

Based on the evidence of safety and efficacy provided by the preclinical research, VIDATOX 30 CH was applied in a controlled study of 174 cancer patients of both sexes with histopathological diagnosis confirmed, which was administered 5 sublingual drops every 12 hours during the period 3/12/2007 to 2/2/2010.

Samples were grouped by location, neoplastic families, stage evolution of the disease, treatment received and the presence of cancer neoplasia. At the conclusion of the study period (2 years) lung, prostate, colon, breast and uterus were the most sensitive effect of the product. Similarly, it is demonstrated that administration of medication in 96% of patients, led to a life of greater than 12 months regardless of the location and stage of disease, especially in those patients for whom there were no treatment options available in conventional medicine.

As another important clinical outcome may be mentioned that 90% of patients who received VIDATOX ® 30 CH in the dose given, reported improvement of clinical symptoms based on consultation, and in 62% of them initial pain evolved into a mild form that did not require treatment necessarily to their relief, while 27% said absence of pain.

This latter aspect of his enormous influence on the quality of life of patients, is important to detail that 62% of patients with presence of severe pain with continuing need for medication (level 2), after treatment passed to the condition of minimal or moderate pain without medication (level 1).

Generally in patients comprising the sample are referred to herein has been:

• Improvement in pain
• Improvement of inflammation
• Improvement in hematologic parameters
• Improvement of appetite
• Improvement of general health
• Improved function in organs and systems affected
• Weight gain
• Reduction of cough
• Desire to live

We conclude that the use of 30 CH VIDATOX ®, can improve the quality of life, increase survival and slow tumor growth without the appearance of patients today cause undesirable symptoms and cytostatics radiation to which we subject our patients.

In this context, one should not ignore the massive consumption of the product for more of 26,000 people, from October 1 to April 10 of 2010 without reported adverse effects to date of application, confirming the preclinical experimental results.

MSC: Fabio De J. Linares Pazoz Production manager Laboratories Homeopathic Products LABIOFAM-CUBA

Inhibition of basophil activation by histamine: a sensitive and reproducible model for the study of the biological activity of high dilutions

Inhibition of basophil activation by histamine: a sensitive and reproducible model for the study of the biological activity of high dilutions

J. Sainte-Laudy^1, , , Ph Belon²

Received 8 July 2009; revised 21 September 2009; Accepted 23 September 2009. Available online 27 November 2009.

Background

At the beginning of this series of experiments we were looking for a model based on the use of purified commercially available compounds based on a fully described and accepted pharmacological model to study of the biological effect of high dilutions. Negative feedback induced by histamine, a major pro-inflammatory mediator, on basophils and mast cells activation via an H2 receptor me these criteria. The simplest way of measuring basophil activation in the early 1980's was the human basophil activation test (HBDT).

Objectives

Our major goal was first to study the biological effect of centesimal histamine dilutions beyond the Avogadro limit, on the staining properties of human basophils activated by an allergen extract initially house dust mite, then an anti-IgE and N-formyl-Met-Leu-Phe (fMLP). Technical development over the 25 years of our work led us to replace the manual basophil counting by flow cytometry. The main advantages were automation and observer independence. Using this latter protocol our aim was to confirm the existence of this phenomenon and to check its specificity by testing, under the same conditions, inactive analogues of histamine and histamine antagonists. More recently, we developed an animal model (mouse basophils) to study the effect of histamine on histamine release.

Methods and results

For the HBDT model basophils were obtained by sedimentation of human blood taken on EDTA and stained with Alcian blue. Results were expressed in percentage activation. Histamine dilutions tested were freshly prepared in the lab by successive centesimal dilutions and vortexing. Water controls were prepared in the same way. For the flow cytometric protocol basophils were first labeled by an anti-IgE FITC (basophil marker) and an anti-CD63 (basophil activation marker). Results were expressed in percentage of CD63 positive basophils. Another flow cytometric protocol has been developed more recently, based on basophil labeling by anti-IgE FITC (fluorescein isothiocyanate) and anti-CD203 PE (another human basophil activation marker). Results were expressed in mean fluorescence intensity of the CD203c positive population (MFI-CD203c) and an activation index calculated by an algorithm. For the mouse basophil model, histamine was measured spectrofluorimetrically.

The main results obtained over 28 years of work was the demonstration of a reproducible inhibition of human basophil activation by high dilutions of histamine, the effect peaks in the range of 15–17CH. The effect was not significant when histamine was replaced by histidine (a histamine precursor) or cimetidine (histamine H2 receptor antagonist) was added to the incubation medium. These results were confirmed by flow cytometry. Using the latter technique, we also showed that 4-Methyl histamine (H2 agonist) induced a similar effect, in contrast to 1-Methyl histamine, an inactive histamine metabolite.

Using the mouse model, we showed that histamine high dilutions, in the same range of dilutions, inhibited histamine release.

Conclusions

Successively, using different models to study of human and murine basophil activation, we demonstrated that high dilutions of histamine, in the range of 15–17CH induce a reproducible biological effect. This phenomenon has been confirmed by a multi-center study using the HBDT model and by at least three independent laboratories by flow cytometry. The specificity of the observed effect was confirmed, versus the water controls at the same dilution level by the absence of biological activity of inactive compounds such as histidine and 1-Methyl histamine and by the reversibility of this effect in the presence of a histamine receptor H2 antagonist.

Keywords: Human basophil; Mouse basophil; High dilutions; Homoeopathy; Histamine; Flow cytometry; Histamine release; IL4 release

http://www.sciencedirect.com/science/article/pii/S1475491609000952

Influence of Potassium Dichromate on Tracheal Secretions in Critically Ill Patients*

Influence of Potassium Dichromate on Tracheal Secretions in Critically Ill Patients*Michael Frass, MD; Christoph Dielacher, RN; Manfred Linkesch, MD; Christian Endler, PhD; Ilse Muchitsch, PhD; Ernst Schuster, PhD; and Alan Kaye, MD Background: Stringy, tenacious tracheal secretions may prevent extubation in patients weaned from the respirator. This prospective, randomized, double-blind, placebo-controlled study with parallel assignment was performed to assess the influence of sublingually administered potassium dichromate C30 on the amount of tenacious, stringy tracheal secretions in critically ill patients with a history of tobacco use and COPD. Methods: In this study, 50 patients breathing spontaneously with continuous positive airway pressure were receiving either potassium dichromate C30 globules (group 1) [Deutsche Ho- mo ̈opathie-Union, Pharmaceutical Company; Karlsruhe, Germany] or placebo (group 2). Five globules were administered twice daily at intervals of 12 h. The amount of tracheal secretions on day 2 after the start of the study as well as the time for successful extubation and length of stay in the ICU were recorded. Results: The amount of tracheal secretions was reduced significantly in group 1 (p < 0.0001). Extubation could be performed significantly earlier in group 1 (p < 0.0001). Similarly, length of stay was significantly shorter in group 1 (4.20 􏰀 1.61 days vs 7.68 􏰀 3.60 days, p < 0.0001 [mean 􏰀 SD]). Conclusion: These data suggest that potentized (diluted and vigorously shaken) potassium dichromate may help to decrease the amount of stringy tracheal secretions in COPD patients. (CHEST 2005; 127:936–941) Key words: COPD; double-blind, randomized, placebo-controlled study; extubation; homeopathy; tracheal secretions Abbreviations: APACHE 􏰁 acute physiology and chronic health evaluation; BMI 􏰁 body mass index; CPAP 􏰁 con- tinuous positive airway pressure; Fio2 􏰁 fraction of inspired oxygen

Research Study on the remedy "Plumbum metallicum"

Homeopathic pathogenetic trial of Plumbum metallicum: the complete 2000 trial with a synthesis of the original 1828 trial

ABSTRACT Background: in a previous paper we reported the statistical analysis and other distribution data of a homeopathic pathogenetic trial (HPT) of Plumbum metallicum 30cH carried out by our group. However, at that time we did not report the resulting pure materia medica, i.e., the totality of symptoms elicited by the tested medicine on healthy volunteers. Aim: to communicate to the homeopathic community the full record of symptoms collected in our HPT of Plb. Methods: methods to collect and select symptoms have been reported in the previous paper. In synthesis were excluded all previous common symptoms of volunteers, even with slight differences, and selected only those that were really unknown, never seen, unusual or very strange for the prover. In this paper special emphasis was given to new symptoms as well as unusual or repeated dreams, while in the previous paper special emphasis was given to repeated and crossed symptoms. Results: symptoms are reported in their chronological order of appearance in each volunteer. 37 new symptoms were found, useful to update Homeopathic Repertories. It is also included a synthesis of the original HPT of Plb carried out in 1828 in order to make available the full experimental materia medica currently existing. Conclusions: the new HPT, besides widening the pathogenetic picture of Plb (skin and mucosae symptoms), also allowed us to give new and deeper meanings to some of the symptoms reported in the original trial, such as Anxiety, Activity, Depression, Slowness, Gastro-oesophageal problems, Colitis. The dreams complete the remedy image, mainly in work, religion and sexual themes. Up to the present time there is no peer-reviewed publication devoted to HPTs. For this reason, researchers are compelled to publish HPTs as private editions. This results in poor control of the quality of publications and a lack of standards on how to present the results of HPTs. Key words: Homeopathic pathogenetic trials, Plumbum metallicum, retrial, clinical indications.